costs ($347) due to longer lifetimes, and had a direct medical cost reduction (-$1,716) due to improved glycemic control. **CONCLUSIONS:** The AUTONOMY Q1D titration algorithm offers a simple and effective approach to assist patients requiring basal-bolus therapy in adjusting their meal-time insulin dose. Results from our study indicate that compared to published delays in treatment modification or escalation, an adaptive daily titration algorithm can lead to better outcomes at lower costs.

PDB36

COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT OF AN EXTENDED VERSUS IMMEDIATE RELEASE FORMULATION OF METFORMIN IN TYPE-2 DIABETES MELLITUS TREATMENT, FROM THE PERSPECTIVE OF THE BRAZILIAN PUBLIC HEALTH SYSTEM

Fujii RK[1], Restrepo M[2], Fernandes RA[3], Haas L[3], Pepe C[4], Junqueira M[1]

[1]*Merck Serono, SÃ£o Paulo, Brazil,* [2]*Merck Serono, Bogota, Colombia,* [3]*Grupo Resulta, SÃ£o Paulo, Brazil,* [4]*NewBD/Medinsight - Grupo Resulta, SÃ£o Paulo, Brazil*

OBJECTIVES: The IDF global guideline for type-2 DM considers metformin as first-line therapy, without contraindications, but gastrointestinal intolerance occurs in 20-30% of patients receiving an immediate release of metformin, being a possible barrier to treatment adherence. Glucophage® XR is an extended-release formulation of metformin IR, with the same antidiabetic efficacy, a flexible dosing range to assist in treatment titration with superior gastrointestinal tolerability, contributing to greater compliance. The aim of this study is to evaluate the cost-effectiveness (CE) and budget impact (BI) of metformin XR compared to metformin IR, in adults with type-2 DM, from the perspective of the public health system in Brazil. **METHODS:** The outcomes of interest were days on treatment; number of events (stroke, myocardial infarction, heart failure, peripheral mononeuropathy, retinopathy, blindness, diabetic foot, amputation, diabetic nephropathy and renal disease); number of full-lifetime-patients without treatment (non-compliance); number of full-lifetime-patients with controlled diabetes; and life years. Efficacy data were obtained from literature review and unit costs were obtained from official price lists. The time horizon of the CE and BI model was 30 and 10 years respectively. A 5% annual discount rate was applied to costs and benefits in the CE model. **RESULTS:** Glucophage® XR increased overall survival in 0.75 day and assured more 1,631 days on treatment, per patient, during lifetime period. Also, reduced 6,249 events and allowed more 143 full-lifetime-patients with controlled type-2 DM, per 1,000 patients. Glucophage® XR was dominant vs. Metformin IR, resulting in saving approximately 5.5% (BRL 10,961,011 per patient). Additionally, the use of Glucophage® XR in patients with type-2 DM resulted in saving of approximately BRL 3,787,758,740.88 in the period from 2014 to 2025. **CONCLUSIONS:** Glucophage® XR showed dominance versus metformin IR due to a safer profile leading to better tolerance, compliance and better health outcomes.

PDB37

DIRECT MEDICAL COSTS ASSOCIATED WITH DIABETIC COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES IN THE US VERSUS SOUTH KOREA

Chang C[1], Lee S[1], Kim C[2], Suh D[1]

[1]*Chung-Ang University, Seoul, South Korea,* [2]*Catholic University College of Medicine, Seoul, South Korea*

OBJECTIVES: To estimate and compare annual direct medical costs associated with diabetic complications in patient with type 2 diabetes in the USA and South Korea. **METHODS:** Data were obtained from the 2010-2011 Medical Expenditure Panel Survey (MEPS), which is a nationally representative sample of ambulatory population in the US, and the 2010-2011 Korea Health Panel (KHP) which contains health service use and expenditures for a representative sample of Korea. Using ICD-9 CM codes, patients were classified as patients with microvascular complications only (nephropahty, neuropathy, retinopahty, or peripheral vascular disease), macrovascular complications only (cardiovascular disease and cerebrovascular disease), both complications, and without complications. Direct medical costs included costs associated with hospitalization, outpatient visits, emergency room visits, and drugs. To compare costs of diabetic patients with and without complications, direct medical costs were estimated using the generalized linear model (GLM) with log link function and gamma distribution after adjusting for patient characteristics. **RESULTS:** Among 3,864 and 2,060 patients with diabetes in the US and Korea, respectively, 87.0% and 61.9% patients had no complications; 4.5% and 17.7% patients had microvascular complications only; 8.3% and 13.6% had macrovascular complications only; and 0.2% and 6.8% had both complications. The average annual direct medical costs per patient were $8,191 in the US and $1,590(US$1=KRW1,000) in Korea. After adjusting for patients' characteristics, annual direct medical costs associated with microvascular complications were 2.36(US) and 2.05(Korea) times greater; macrovascular complications were 2.70(US) and 1.76 times(Korea) greater, while both complications were 5.66(US) vs. 3.08(Korea) times greater than those without complications, respectively. **CONCLUSIONS:** Direct medical treatment costs in patients with diabetic microvascular or macrovascular complications were significantly higher than those without diabetes complications, and the magnitudes of additional costs are different between US and Korea. Providing proper treatment of diabetes to prevent or delay diabetic complications is important to minimize treatment costs of diabetes.

PDB39

ECONOMIC IMPACT OF DAPAGLIFLOZIN VS. OTHER ANTIDIABETIC DRUGS FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES

Lin J[1], Dhankhar P[2], Bell K[2], Chhatwal J[3], Lingohr-Smith M[1]

[1]*Novosys Health, Green Brook, NJ, USA,* [2]*AstraZeneca, Fort Washington, PA, USA,* [3]*The University of Texas MD Anderson Cancer Center, Houston, TX, USA*

OBJECTIVES: The objective of this study was to evaluate the short-term economic impact of treatment of type 2 diabetes (T2DM) patients with dapagliflozin (dapa) vs. other antidiabetic drugs, including daily dosage glucagon-like peptide-1 (GLP-1) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZDs), and sulfonylureas (SUs). **METHODS:** An economic model (1-year time horizon) was developed to evaluate differences in annual medical costs and costs per quality-adjusted life-year (QALY) gain among T2DM patients treated with dapa vs. other antidiabetic drugs. Changes in clinical endpoints, including HbA1c, weight, systolic blood pressure (SBP), and hypoglycemia risk, associated with 52-week treatment with the different antidiabetic drugs were obtained from a network meta-analysis. Annual medical costs and QALYs for changes in clinical endpoints were obtained from published literature. **RESULTS:** For one year of treatment of a T2DM patient, medical costs associated with changes in HbA1c, weight, SBP, and hypoglycemia risk for dapa were -$173 (Confidence interval: -$1,125, $747) vs. GLP-1 agonists, -$1,061 (-$1,859, -$362) vs. DPP-4 inhibitors, -$1,524 (-$2,552, -$649) vs. TZDs, and -$2,300 (-$3,131, -$1,574) vs. SUs. Results from univariate and multivariable sensitivity analyses showed that the estimates of the medical cost differences were most affected by variations in weight and SBP changes, but were generally robust when model parameters were varied. Treatment with dapa was cost saving vs. other antidiabetic drugs when only medical costs were considered. When drug costs were included, treatment with dapa remained either cost saving (vs. GLP-1 agonists and DPP-4 inhibitors) or cost-effective vs. TZDs ($10,007 per QALY), vs. SUs ($9,650 per QALY). **CONCLUSIONS:** Treatment of T2DM patients with dapa was associated with reduced medical costs vs. daily dosage GLP-1 agonists, DPP-4 inhibitors, TZDs, and SUs. When drug costs were included, treatment with dapa was cost saving vs. daily dosage GLP-1 agonists and DPP-4 inhibitors and cost-effective vs. TZDs and SUs.

PDB40

EVALUATION OF THE ANNUAL COST OF MEDICINES USED IN TREATMENT OF TYPE 2 DIABETES MELLITUS IN INDIA

Hussain S, Kumari S

National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India

OBJECTIVES: To compute the cost of medicines used in the treatment of T2DM and study the variation in the costs. **METHODS:** Indian Council of Medical Research (ICMR) and International Diabetes Federation (IDF) guidelines were used to understand the treatment of T2DM. Current Index of Medical Specialities (CIMS) Apr-July2014 issue and Indian Drug Review (IDR) issue 2, Feb2014 were used to capture the prices of medicines available in the Indian market. The annual cost of treatment and variation in the annual cost of drugs was studied. **RESULTS:** IDF recommends first line treatment with metformin 500mg twice a day. The annual cost of treatment with metformin was found to be Rs.467-2336. A variation of 400% is noted in the least-highest cost of metformin. Glimepiride 2mg OD is used as a second line treatment and its annual cost ranges between Rs.458-4851. It shows maximum variation of 960% in the least-highest cost. Likewise, third line treatment can be started either with α-Glucosidase inhibitor or DPP4 inhibitor or Thiazolidine group of drugs. Annual cost of treatment with Pioglitazone 15mg was found to be Rs.365-2555. Among the third line category of drugs, Pioglitazone 15mg shows maximum variation of 600% in the least-highest cost. Used as a fixed dose combination (FDC), Glimepiride+Metformin (1+500 mg) showed maximum price variation of 529%. **CONCLUSIONS:** It was concluded that a maximum of 11 fold variation was observed in the least-highest costs of treatment with Glimepiride 2mg in the year 2014. Wide variation exists in the percentage price variation of same drug manufactured across the different brands.

PDB41

ECONOMIC BURDEN AND POOR QUALITY OF LIFE ASSOCIATED WITH ACROMEGALY IN THE UNITED STATES

Liu S[1], Xu Y[2], Sisco J[3], Begelman SM[2], Shi L[4]

[1]*Tulane University, NEW ORLEANS, LA, USA,* [2]*Genentech Inc., South San Francisco, CA, USA,* [3]*Acromegaly Community, Grove, OK, USA,* [4]*Tulane University, New Orleans, LA, USA*

OBJECTIVES: To assess economic burden and quality of life (QoL) associated with acromegaly in the United States. **METHODS:** A web-based cross-sectional survey was conducted from August –October, 2014. Patient-reported information on acromegaly-related economic burden was collected. The direct and indirect costs per patient over the past 3 months included out-of-pocket cost, sick leave, leave of absence, direct loss of job due to acromegaly, unemployment, assistance to perform household chores, and family member loss of income. The QoL was assessed by Acromegaly Quality of Life (AcroQoL) and EQ-5D questionnaires. Descriptive analysis was used. **RESULTS:** A total of 106 patients completed the survey (mean age: 46 years, female: 76%). The annualized office visits per person to physicians, nurses and other health professionals was 11.8, 3.4 and 6.6 visits, respectively. The acromegaly patients had 0.7 emergency room visits, 0.3 hospital admissions and length of hospital stay of 1.8 days. Annualized healthcare out-of pocket cost was $1,790/person. The average number of days unable to work was 34 days with estimated income loss $6,702 /person-year. The average annual loss of income due to direct loss of job, unemployment disability, household chores, and income loss of family members was $6,106, $10,653, $1,685, and $472/person, respectively. As compared with low-symptom group, symptom 0-3 (n=41), the high-symptom group with 4+ symptoms (n=65) had significantly higher costs by category (loss of job: $8,876 vs. $1,717, p=0.017; unemployment disability: $17,102 vs. $429, p=0.003; household chores: $540 vs. $233, p=0.0003; family members' loss: $128 vs. $23, p=0.028). The average EQ-5D index score and global score of AcroQoL were 0.62±0.23 and 38.61±22.39, respectively. Patients reporting 4 + symptoms had lower QoL scores as compared with those with fewer symptoms (EQ-5D: 0.53 vs. 0.75, p<0.0001; AcroQoL: 27.38 vs. 56.43, p<0.0001). **CONCLUSIONS:** Patients with acromegaly experienced high economic burden and poor quality of life.

PDB42

ESTIMATING CLINICAL AND ECONOMIC OUTCOMES FOLLOWING A DIABETES-RELATED VASCULAR COMPLICATION

Perk S[1], Murphy DR[2], Gahn JC[2], Yu X[2], Smolen HJ[2]

[1]*Medical Decision Modeling, Indianpolis, IN, USA,* [2]*Medical Decision Modeling Inc., Indianapolis, IN, USA*

OBJECTIVES: Type 2 diabetes mellitus (T2DM) is a prevalent disease affecting over 25 million people in the United States. Diabetes inflicts a heavy economic burden